Overview

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis

Phase:

Phase 2

Details

Lead Sponsor:

UCB Biopharma S.P.R.L.

Collaborators:

Parexel
PAREXEL International (IRL) Limited